Tamoxifen downregulates TGF-β production in keloid fibroblasts

Dorothy Chau, John S. Mancoll, Steve Lee, Jiangang Zhao, Linda Phillips, George K. Gittes, Michael T. Longaker

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Keloids occur only in humans and are characterized by fibroblast overproduction of collagen types I and III. Keloid fibroblasts have been shown to make elevated levels of transforming growth factor beta (TGF-β), a growth factor known to promote extracellular matrix production and fibrosis. Thus, the pathophysiology underlying keloid formation may be driven by the biological activity of TGF-β. Tamoxifen, a synthetic, nonsteroidal antiestrogen has been shown to inhibit keloid fibroblast proliferation and decrease collagen production. The purpose of this study was to determine if a mechanism by which tamoxifen decreases keloid collagen production is through a downregulation of TGF-β. Through a luciferase TGF-β bioassay we found that 4 μM of tamoxifen generated a 49% reduction in total TGF-β activity and 8 μM generated an 85% reduction compared with controls. Thus we propose that one of the mechanisms by which tamoxifen decreases keloid fibroblast collagen synthesis is by decreasing TGF-β production.

Original languageEnglish (US)
Pages (from-to)490-493
Number of pages4
JournalAnnals of Plastic Surgery
Volume40
Issue number5
DOIs
StatePublished - 1998

Fingerprint

Keloid
Tamoxifen
Transforming Growth Factor beta
Down-Regulation
Fibroblasts
Collagen
Collagen Type III
Estrogen Receptor Modulators
Collagen Type I
Luciferases
Biological Assay
Extracellular Matrix
Intercellular Signaling Peptides and Proteins
Fibrosis

ASJC Scopus subject areas

  • Surgery

Cite this

Chau, D., Mancoll, J. S., Lee, S., Zhao, J., Phillips, L., Gittes, G. K., & Longaker, M. T. (1998). Tamoxifen downregulates TGF-β production in keloid fibroblasts. Annals of Plastic Surgery, 40(5), 490-493. https://doi.org/10.1097/00000637-199805000-00008

Tamoxifen downregulates TGF-β production in keloid fibroblasts. / Chau, Dorothy; Mancoll, John S.; Lee, Steve; Zhao, Jiangang; Phillips, Linda; Gittes, George K.; Longaker, Michael T.

In: Annals of Plastic Surgery, Vol. 40, No. 5, 1998, p. 490-493.

Research output: Contribution to journalArticle

Chau, D, Mancoll, JS, Lee, S, Zhao, J, Phillips, L, Gittes, GK & Longaker, MT 1998, 'Tamoxifen downregulates TGF-β production in keloid fibroblasts', Annals of Plastic Surgery, vol. 40, no. 5, pp. 490-493. https://doi.org/10.1097/00000637-199805000-00008
Chau, Dorothy ; Mancoll, John S. ; Lee, Steve ; Zhao, Jiangang ; Phillips, Linda ; Gittes, George K. ; Longaker, Michael T. / Tamoxifen downregulates TGF-β production in keloid fibroblasts. In: Annals of Plastic Surgery. 1998 ; Vol. 40, No. 5. pp. 490-493.
@article{57067401e0ca46fba36e4513160ea268,
title = "Tamoxifen downregulates TGF-β production in keloid fibroblasts",
abstract = "Keloids occur only in humans and are characterized by fibroblast overproduction of collagen types I and III. Keloid fibroblasts have been shown to make elevated levels of transforming growth factor beta (TGF-β), a growth factor known to promote extracellular matrix production and fibrosis. Thus, the pathophysiology underlying keloid formation may be driven by the biological activity of TGF-β. Tamoxifen, a synthetic, nonsteroidal antiestrogen has been shown to inhibit keloid fibroblast proliferation and decrease collagen production. The purpose of this study was to determine if a mechanism by which tamoxifen decreases keloid collagen production is through a downregulation of TGF-β. Through a luciferase TGF-β bioassay we found that 4 μM of tamoxifen generated a 49{\%} reduction in total TGF-β activity and 8 μM generated an 85{\%} reduction compared with controls. Thus we propose that one of the mechanisms by which tamoxifen decreases keloid fibroblast collagen synthesis is by decreasing TGF-β production.",
author = "Dorothy Chau and Mancoll, {John S.} and Steve Lee and Jiangang Zhao and Linda Phillips and Gittes, {George K.} and Longaker, {Michael T.}",
year = "1998",
doi = "10.1097/00000637-199805000-00008",
language = "English (US)",
volume = "40",
pages = "490--493",
journal = "Annals of Plastic Surgery",
issn = "0148-7043",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Tamoxifen downregulates TGF-β production in keloid fibroblasts

AU - Chau, Dorothy

AU - Mancoll, John S.

AU - Lee, Steve

AU - Zhao, Jiangang

AU - Phillips, Linda

AU - Gittes, George K.

AU - Longaker, Michael T.

PY - 1998

Y1 - 1998

N2 - Keloids occur only in humans and are characterized by fibroblast overproduction of collagen types I and III. Keloid fibroblasts have been shown to make elevated levels of transforming growth factor beta (TGF-β), a growth factor known to promote extracellular matrix production and fibrosis. Thus, the pathophysiology underlying keloid formation may be driven by the biological activity of TGF-β. Tamoxifen, a synthetic, nonsteroidal antiestrogen has been shown to inhibit keloid fibroblast proliferation and decrease collagen production. The purpose of this study was to determine if a mechanism by which tamoxifen decreases keloid collagen production is through a downregulation of TGF-β. Through a luciferase TGF-β bioassay we found that 4 μM of tamoxifen generated a 49% reduction in total TGF-β activity and 8 μM generated an 85% reduction compared with controls. Thus we propose that one of the mechanisms by which tamoxifen decreases keloid fibroblast collagen synthesis is by decreasing TGF-β production.

AB - Keloids occur only in humans and are characterized by fibroblast overproduction of collagen types I and III. Keloid fibroblasts have been shown to make elevated levels of transforming growth factor beta (TGF-β), a growth factor known to promote extracellular matrix production and fibrosis. Thus, the pathophysiology underlying keloid formation may be driven by the biological activity of TGF-β. Tamoxifen, a synthetic, nonsteroidal antiestrogen has been shown to inhibit keloid fibroblast proliferation and decrease collagen production. The purpose of this study was to determine if a mechanism by which tamoxifen decreases keloid collagen production is through a downregulation of TGF-β. Through a luciferase TGF-β bioassay we found that 4 μM of tamoxifen generated a 49% reduction in total TGF-β activity and 8 μM generated an 85% reduction compared with controls. Thus we propose that one of the mechanisms by which tamoxifen decreases keloid fibroblast collagen synthesis is by decreasing TGF-β production.

UR - http://www.scopus.com/inward/record.url?scp=0031925970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031925970&partnerID=8YFLogxK

U2 - 10.1097/00000637-199805000-00008

DO - 10.1097/00000637-199805000-00008

M3 - Article

VL - 40

SP - 490

EP - 493

JO - Annals of Plastic Surgery

JF - Annals of Plastic Surgery

SN - 0148-7043

IS - 5

ER -